Research develops a novel vaccine strategy to effectively prevent SARS-CoV-2 intranasal infection

Emergency-use vaccines are effective against COVID-19, but vaccine-induced prophylaxis remains suboptimal against SARS-CoV-2 nasal infections

Study shows a combined strategy of intramuscular PD-1-based receptor binding domain DNA vaccine (PD1-RBD-DNA) and intranasal live attenuated influenza vaccine-based vaccine (LAIV-HK68-RBD) Or induce the strongest mucosal broad-spectrum neutralizing antibodies and lung-resident memory CD8 T cells, which may be effective in preventing the nasal infection challenge of live SARS-CoV-2 in two animal models

Today, the COVID-19 pandemic has caused more than 275 million infections worldwide, and 5.

In this study, the investigators show that compared with current COVID-19 vaccine strategies, systemic and mucosal antibodies IgA/IgG and lung-resident multifunctional memory CD8 T cells were mainly induced by a heterotypic combination strategy.

The researchers believe that the use of nasal spray vaccine to establish protection in the upper respiratory tract is a key strategy to reduce SARS-CoV-2 infection and transmission, and is very important for the ultimate control of the COVID-19 pandemic; Taken together, the results of this study show that nasal Influenza vaccine-based booster vaccines may induce mucosal and systemic immunity to effectively prevent SARS-CoV-2 infection and transmission in the upper and lower respiratory tracts

Note: The original text has been deleted

Original source:

Runhong Zhou, Pui Wang, Yik-Chun Wong, et al.